Krystal Biotech Reports Second Quarter 2018 Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
69
Krystal Biotech Reports Second Quarter 2018 Financial Results and Provides Corporate Update

First two patients enrolled in Phase 1/2 clinical study of KB103, a first-in-class topical gene therapy for the treatment of dystrophic epidermolysis bullosa. 

PITTSBURGH, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech (NASDAQ: KRYS ), a gene therapy company advancing  “off-the-shelf” topical and intra-dermal treatments for skin diseases, today reported financial results for the second quarter ended June 30, 2018, and provided an update on the company’s corporate progress.  

Commenting on second quarter results, Krish S. Krishnan, chairman and chief executive officer of Krystal Biotech, said, “2018 is a year of execution for Krystal as we strive to achieve three important value-creating catalysts. First and foremost, in the clinic, we intend to announce interim safety and efficacy results from the KB103 Phase 1/2 study for the treatment of dystrophic epidermolysis bullosa (DEB) by Q4 2018. In addition, we completed our pre-IND meeting with the FDA on KB105, our second pipeline product for the treatment of TGM-1 deficient autosomal recessive congenital ichthyosis (ARCI), and anticipate filing our IND in Q4. Finally, construction of the GMP facility to manufacture clinical grade products for Krystal’s pipeline programs has begun and is anticipated to be complete by the end of 2018.” Mr. Krishnan continued, “I believe Krystal’s approach of using an 'off-the-shelf' topical gene therapy approach to treating debilitating skin diseases is unique in the industry and we are only beginning to unlock the value of our technology and pipeline.”

Recent Corporate Highlights 

  • First two patients enrolled in Phase 1/2 clinical study of KB103, a first-in-class topical gene therapy for the treatment of DEB.
  • U.S. FDA grants Fast Track Designation for Krystal Biotech’s KB103 for the treatment of DEB.
  • IND on KB105, a topical gene therapy for the treatment of TGM-1 deficient ARCI, to be filed in Q4 2018 following completion of pre-IND meeting with the U.S. FDA.
  • Construction of the GMP facility to manufacture clinical grade products for Krystal’s pipeline programs to be complete in Q4 2018.
  • David Maheu joins the Krystal team as vice-president, process development and manufacturing operations.
    • 17+ years at Amgen working on process development and manufacturing work on Imlygic, a genetically modified HSV-1 virus, approved for commercial distribution in US and Europe and targeted against metastatic melanoma.
    • 2 years at MilliporeSigma Inc. as head of virus and gene therapy bioprocessing.

Financial results for the quarter ended June 30, 2018

  • Cash, cash equivalents and short-term investments totaled $45.5 million at June 30, 2018, compared with $47.2 million at March 31, 2018.
  • Research and development expenses for the second quarter were $1.5 million.
  • General and administrative expenses for the second quarter were $0.9 million.
  • Net losses for the quarters ended June 30, 2018 and 2017 were $2.3 million and $0.8 million, respectively, or $0.22 per common share (basic and diluted) for both periods.

For further details on the company’s financials, please refer to Form 10Q filed with the SEC.

About KB103 KB103 is Krystal’s lead product candidate, currently in preclinical development and seeks to use gene therapy to treat dystrophic epidermolysis bullosa, or DEB, an incurable skin blistering condition caused by a lack of collagen in the skin.  KB103 is a replication-defective, non-integrating viral vector that has been engineered using the HSV-1 virus employing Krystal’s STAR-D platform to deliver functional human COL7A1 genes directly to the patients’ dividing and non-dividing skin cells.  Krystal’s vector can penetrate skin cells more efficiently than other viral vectors.  Its high payload capacity allows it to accommodate large or multiple genes and its low immunogenicity makes it a suitable choice for direct and repeat delivery to the skin.

About Dystrophic Epidermolysis Bullosa, or DEB Dystrophic epidermolysis bullosa, or DEB, is an incurable, often fatal skin blistering condition caused by a lack of collagen protein in the skin. It is caused by mutations in the gene coding for type VII collagen, or COL7, a major component of the anchoring fibrils, which anchor the epidermis to the underlying dermis, and provide structural adhesion in a normal individual. The lack of COL7 in DEB patients causes blisters to occur in the dermis as a result of separation from the epidermis.  This makes the skin incredibly fragile, leading to blistering or skin loss at the slightest friction or knock. It is progressive and incredibly painful.

The most severe form of DEB is recessive DEB, or RDEB, which is caused by null mutations in the COL7A1 gene.  DEB also occurs in the form of dominant DEB, or DDEB, which is considered to be a milder form of DEB.  There are no known treatments, which affect the outcome of either form of the disease, and the current standard of care for DEB patients is limited to palliative treatments.  Krystal is developing KB-103 for the treatment of the broad DEB population, including both recessive and dominant forms of the disease.    

About Lamellar Ichthyosis Lamellar ichthyosis (LI) is an autosomal recessive disorder that is apparent at birth and is present throughout life. There are 22 known types of LI, a number of which are known to be caused by defects in one of several skin-related genes. LI usually appears in the first few days of life, lasts lifelong and in certain variants can be very severe. A newborn with LI is born encased in a collodion membrane that sheds within 10-14 days. The shedding of the membrane reveals generalized scaling with variable redness of the skin. The scaling may be fine or plate-like, resembling fish skin. Although the disorder is not life threatening, it is quite disfiguring and causes considerable psychological stress to affected patients. There are no approved treatments for LI and the current standard of care remains palliative treatments to manage symptoms.

About the STAR-D Gene Therapy Platform  Krystal has developed a proprietary gene therapy platform, the Skin TARgeted Delivery platform, or STAR-D platform, that consists of an engineered viral vector and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases. The company believes that the STAR-D platform provides an optimal approach for treating dermatological conditions due to the nature of the HSV-1 viral vector it has created. Certain inherent features of the HSV-1 virus, combined with the ability to strategically modify the virus in the form employed as a gene delivery backbone, provide the STAR-D platform with several advantages over other viral vector platforms for use in dermatological applications.

About Krystal Biotech Krystal Biotech, Inc. (NASDAQ: KRYS ) is a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases. For more information, please visit  http://www.krystalbio.com . 

Forward-Looking Statements This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding the development of our product candidates, including KB103 and KB105, including statements regarding our plans to initiate a clinical trial of KB103 in 2018 and to file an IND for KB105 during this calendar year and our plans to develop a GMP manufacturing facility over the next 12 months.  You can identify forward-looking statements because they contain words such as “believes” and “expects.” Forward-looking statements are based on Krystal’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in Krystal’s periodic filings with the Securities and Exchange Commission, including its registration statement on Form S-1 and its Form 10-K, under the caption “Risk Factors.”

CONTACT Ashley R. Robinson  LifeSci Advisors arr@lifesciadvisors.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

RLX Revenue Soars, but European Margins Need Proof

Updated Category News Views 104

Revenue can wear a fancy suit while earnings arrive in work boots, and RLX Technology's third quarter is exactly that kind of report. The newly consolidated European distribution business pushed third-quarter revenue to RMB1.92 billion, up 69.7% year over year. That is a real jump, not pocket change. But the same acquisition also changed the mix, squeezed the blended...

Continue Reading
Rosenblatt Book Puts Vegas Casino Blind Spots on Display

Updated Category News Views 143

A locked casino floor is supposed to make secrets expensive. That is why the pitch behind ROSENBLATT lands with a little more weight than the usual Vegas chest-thumping: the coming memoir says Darryl Rosenblatt became a million-dollar gambler while using none of his own money, and that casino operators did not grasp the full shape of what had happened for years. Take a...

Continue Reading
Huhtamaki Maps Its 2027 Reporting Dates for Investors

Updated Category News Views 84

A calendar release rarely makes the pulse race, but it tells shareholders when the curtain will actually go up. Huhtamäki Oyj has laid out its 2027 financial reporting timetable, and the useful part is its plainness: investors now know the handful of dates when management will have to put numbers, not broad ambitions, in front of the market. For a packaging company, that...

Continue Reading
AIM Academy Accreditation Signals a Broader Quality Push

Updated Category News Views 50

Early-childhood education does not hand out many clean, easily comparable scorecards, which is precisely why AIM Academy’s new Cognia recognition deserves a closer look. The Alabama provider has earned Cognia Initial Accreditation, while its Pike Road center received Accreditation with Merit after its Initial Accreditation Review. That is not a revenue event, not a...

Continue Reading
Industrial Air Compressors: Fix, Rebuild, or Replace

Updated Category News Views 22

A compressor’s ugliest invoice is rarely the one from the service technician. It is the one nobody sees at first: a stalled production line, missed output, overtime, wasted electricity, and a maintenance crew chasing the same machine again next month. Pam Mahood of Waterloo, Iowa-based Compressed Air & Equipment Co. puts the decision where it belongs—not on the price...

Continue Reading
&honey's U.S. Beauty Awards Sweep Puts Distribution in Focus

Updated Category News Views 165

Three glossy-magazine nods may sound fluffy, but shelf momentum is never entirely fluff. Japanese haircare brand &honey says its Deep Moist Shampoo, Treatment and Hair Oil each landed 2026 recognition from Marie Claire, ELLE and Allure. For a consumer brand trying to make an American habit out of a Japanese haircare ritual, that is the sort of validation worth...

Continue Reading
Korla Kiln Gains Show How Cement Efficiency Is Won

Updated Category News Views 79

A cement kiln does not care about corporate slogans; it cares whether the flame holds, the bearings stay alive, and the feed keeps moving. That is why the work at Xinjiang Tianshan Cement's Tashidian branch in Korla deserves a closer look. This is not a glossy tale about a futuristic factory appearing overnight. It is an account of an old, unforgiving industrial process...

Continue Reading
Automus and Google Cloud Put Agents to Work on Oracle

Updated Category News Views 85

Oracle back offices are where shiny AI promises go to earn their keep, or get buried under a mountain of integrations. Automus Consulting’s newly announced collaboration with Google Cloud, unveiled November 20 at Oracle AI World, is aimed squarely at that messy middle. The firm wants to combine its Oracle implementation experience with Google Cloud infrastructure and...

Continue Reading
Lowe's Dec. 9 Conference Puts Strategy on the Clock

Updated Category News Views 167

A Calendar Entry With Real Weight December 9 is not earnings day, but it is the sort of date shareholders ought to circle anyway. Lowe's plans to hold its 2026 Analyst and Investor Conference at 8 a.m. Eastern time in New York City, with a live webcast available for those not sitting in the room. For owners of NYSE:LOW, these gatherings can be more useful than the usual...

Continue Reading
Fromm Day Marks 50 Years of Learning and Connection

Updated Category News Views 88

A city proclamation can be fluffy civic confetti, but this one lands differently. San Francisco declared Nov. 14, 2026, Fromm Day as the Fromm Institute for Lifelong Learning marked its 50th anniversary, and the underlying story is sturdier than a ceremonial photo op. A program that began in 1976 expecting roughly 50 people at an open house drew about 150 students in its...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Dynamics of the Automated Sortation System Market

Updated Category News Views 95

The Growth of the Automated Sortation System Market The automated sortation systems market is on a rapid ascent, projected to rise significantly and reach an estimated USD 5.68 billion by 2032. This thriving market, valued at approximately USD 4.00 billion in the previous year, demonstrates a vigorous compound annual growth rate (CAGR) of 3.99% from 2024 to 2032. The...

Continue Reading
Advancing Biopharmaceutical Manufacturing with New Ontologies

Updated Category News Views 148

Introducing Advanced Biopharmaceutical Manufacturing Ontologies In a groundbreaking development for the biopharmaceutical industry, the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) and Open Applications Group, Inc. (OAGi) have unveiled a set of innovative ontologies aimed at improving data interoperability and analytics. This...

Continue Reading
Illinois Tool Works Prepares for Third Quarter Earnings Call

Updated Category News Views 46

Illinois Tool Works Announces Earnings Webcast Schedule Illinois Tool Works Inc. (NYSE: ITW), a prominent name in global manufacturing, is set to release its third quarter results. The company will issue the results on a Wednesday morning at 7:00 a.m. CDT. Following this important announcement, ITW will host a webcast to discuss the outcomes and insights from their...

Continue Reading
Parry Labs Collaborates with Marines on Advanced Data Solutions

Updated Category News Views 158

Parry Labs Collaborates with Marines on Advanced Data Solutions Parry Labs, a leading defense technology firm known for its innovative hardware and digital infrastructure, has engaged with the United States Marine Corps to explore advanced data transfer techniques. During a recent demonstration involving the Joint Staff J6, Parry Labs worked on the Phantom network gateway...

Continue Reading
Discover Autonomix Medical’s Groundbreaking Presentation at EuroPCR

Updated Category News Views 122

Autonomix Medical's Innovative Contribution to EuroPCR Autonomix Medical, Inc. (NASDAQ: AMIX), a pioneering medical device company, is making waves in the field of interventional cardiology. With a focus on precision nerve-targeted treatments, the company has announced exciting developments that will be showcased in a poster presentation at the renowned EuroPCR. The Event...

Continue Reading